Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-04629991 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| first of three dosing cohorts | OTHER | - |
| second of three dosing cohorts | OTHER | - |
| third of three dosing cohorts | OTHER | - |
| Name | Type | Description |
|---|---|---|
| PF-04629991 | DRUG | Oral; Sequential single dose escalation; three fourteen-day treatment periods per subject in the first cohort; randomized sequence of treatments (one placebo and two PF-04629991 doses) |
Inclusion Criteria: * Healthy non-smoking men and women * body mass index 18-30 kg/m2 Exclusion Criteria: * Women must not be able to have children * no current infections
PF-04629991 is an investigational small molecule developed by Pfizer, Inc. It has been studied in a Phase 1 clinical trial in healthy adult volunteers. The specific disease or condition it is intended to treat has not been publicly disclosed, and it remains in early-stage clinical development.
PF-04629991 is being developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. Pfizer sponsored the Phase 1 study of the compound conducted in Belgium. No partnership or licensing arrangement for this asset has been announced.
PF-04629991 is in Phase 1 clinical development. It is an investigational small molecule and has not been approved by the FDA or any other regulatory agency. The single completed trial was a Phase 1 study in healthy volunteers, and no active trials are currently listed.
PF-04629991 has been evaluated in one clinical trial, NCT00797342, titled A Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-04629991 in Healthy Volunteers. The Phase 1 study enrolled 27 participants in Belgium, was randomized, double-blind, and controlled, and is now completed.
The Phase 1 trial NCT00797342 evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-04629991 in healthy adult volunteers. It enrolled 27 participants of all sexes, aged 18 years and older, in Belgium. The study used a randomized, double-blind, controlled design and has been completed.